LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects

Commercialisation

LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years

322M

worldwide expected cases by 2025

10

minute effectiveness

$7.10B

projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.

ON DEMAND
SOLUTION

LTR Pharma Couple

RAPID ONSET
ACTION

BRING BACK
SPONTANIETY

The Courier Mail | LTR hard sell not required

Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by business reporter Glen Norris over the weekend. Here’s an excerpt: “LTR, which is developing an intranasal spray treatment called SPONTAN, on Friday released data that

Read More »

SPONTAN® achieves positive clinical study results

LTR Pharma (ASX:LTP) has announced extremely positive results from its SPONTAN® pivotal bioequivalence clinical study. Initial analysis has concluded that SPONTAN® achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors.  The results demonstrated that SPONTAN achieves rapid absorption and faster onset of action at a substantially

Read More »

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.